Researchers in Germany conducted a pan-body microbiome analysis, uncovering new microbial species and potential therapies linked to diseases, with implications for diagnostic and therapeutic advancements.
Numinus and Cybin Embark on a Groundbreaking Journey: Pioneering Phase 3 Trials for Major Depressive Disorder | Psychedelic Invest
Vancouver, British Columbia–(Newsfile Corp. – May 30, 2024) – In a significant stride towards transforming mental health care, Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF)